The multiherb anti-inflammatory product Zyflamend was investigated for its anti-proliferative effects on human prostate cancer PC3 cells and specifically evaluated for its effects on eicosanoid metabolism in this prostate cancer cell line. Zyflamend was observed to produce a concentration-dependent inhibition of cloned COX-1, COX-2 and 5-LOX enzyme activities with inhibition of production of 5-HETE being greater than that of PGE 2 formation. Applied to intact PC3 cells, Zyflamend was found to be most potent against 12-LOX, followed by 5-LOX 
INTRODUCTION
Prostate cancer is one of the most significant health risks for aging men in the developed world.
This group has a 1 in 6 lifetime risk of a prostate cancer diagnosis and a 1 in 30 lifetime risk of prostate cancer death (1) . However, accumulating insights into the epidemiology, genetics and molecular pathogenesis of prostate cancer all strongly suggest that it may also be one of the most preventable of all human cancers. While specific dietary components such as lycopene from cooked tomatoes, resveratrol from grapes and red wine and isothiocyanates from cruciferous vegetables have been shown to provide at least limited protection against prostate cancer development (2-5), the use of whole herbs and herbal extracts for the prevention and treatment of prostate cancer is also of great interest. As pointed out by Bemis, et al (6) , the anti-inflammatory activity of many plants available as intact products or as extracts has long been held to be beneficial for prevention of prostate cancer. Her recent research has indicated that Zyflamend®, a unique herbal preparation consisting of ten concentrated herbal extracts (rosemary, tumeric, ginger, holy basil, green tea, hu zhang, Chinese goldthread, barberry, oregano, and Scutellaria baicalensis) contains ingredients that significantly inhibit both COX-1 and COX-2 activities and is associated with induction of apoptosis in LNCap cells. Their study, however, strongly suggested that COX-independent mechanisms such as enhanced expression of p21 and reduced expression of androgen receptor, pStat3 and pKBC α/β also contributed to the observed inhibition of prostate tumor cell proliferation in this hormonally sensitive tumor cell model.
There are many bioactive lipids involved in inflammation associated with prostatitis and early stage prostate cancer. These include the well documented ability of PGE 2 to stimulate tumor Cancer Research 7/13/2006 cell proliferation (7) . This typically occurs through an over-expression of COX-2 in tumors as well the more recent finding of a decrease in PGDH activity, an enzyme responsible for metabolism of PGE 2 (8) . Lipoxygenase products such as 5-HETE from 5-LOX and 12-HETE from 12-LOX have also been shown to contribute to prostate tumor growth (9) (10) (11) (12) . Because 12-HETE has specifically been shown to be associated with prostate cancer proliferation, metastases and angiogenesis, the suggestion that inhibition of 12-LOX represents a potential therapeutic approach in treatment of prostate cancer has recently been made (13) . It is therefore of interest that baicalein, a known inhibitor of 12-LOX, is contained within Scutellaria, a component of Zyflamend.
To better understand the role of selected bioactive eicosanoids in the progression of inflammation towards malignant disease, we have undertaken examination of prostate cell related 'inflammation profiles' using an electrospray tandem mass spectrometry assay that we developed (14, 15) . This method permits determination of "mini-lipidomics" in cell or tissue samples through simultaneous analyses of up to 10 cyclooxygenase, lipoxygenase and/or cytochrome P450 derived eicosanoids at one time without the need for addition of exogenous substrates such as arachidonic acid or linoleic acid. To delineate the role of eicosanoids in human prostate cancer (PC3 cells), we applied this novel approach to determine the effect of Zyflamend on cyclooxygenase and lipoxygenase derived eicosanoids believed to be importance in proliferation of this disease. Our aim was to determine the effects, if any, Zyflamend produces in eicosanoid metabolism beyond inhibition of cyclooxygenase activity.
Our data suggest that in addition to inhibition of COX-1 and COX-2 activities, this multi-herb product also potently blocks 5-LOX and 12-LOX activities. The later finding may be of special 7/13/2006 interest in that suppression of 12-LOX activity was found to be associated specifically with inhibition of tumor cell proliferation and Rb phosphorylation and, thus, return of tumor suppressor activity to hormone refractory PC3 prostate tumor cells.
MATERIALS AND METHODS

Materials.
Zyflamend was provided by the manufacturer (NewChapter, Inc., Brattleboro, VT).
The product is an encapsulated olive-oil based suspension. For all experiments the product was dissolved in dimethyl sulfoxide (DMSO) at 1:2 dilution and then further diluted by 1:1000 in tissue culture medium . Concentrations of this herbal product are described as µl Zyflamend/ml. 
Anti-p21
cip was purchased from Upstate (Lake Placid, NY), anti-p27 kip was purchased from BD Pharmingen (San Diego, CA), anti-Cyclin D1 was purchased from Calbiochem (La Jolla, CA), and anti-β-Actin was purchased from Sigma. 
Proteomics and Protein Phosphorylation Changes
Lysates were collected, by the same method as mentioned previously, and sent to Kinexus 
Eicosanoid Analyses
The effect of Zyflamend on relative formation of PGE2, 5-HETE and 12-HETE by both cloned enzymes and PC3 cells were determined according to the method of Yang et al (15) . Reverse phase liquid chromatography electrospray ionization mass spectrometry was used to determine eicosanoids levels (PGE 2 , 5-HETE, 12-HETE) in cells using a previously published method reported by our laboratory (14, 15) . A Micromass Quattro Ultima tandem mass spectrometer (Waters Corp., Milford, MA) was equipped with an Agilent 1100 HP binary pump HPLC inlet for use in these studies. Eicosanoids were separated using a Luna 3µ phenylhexyl (2 x 150 mm) LC column (Phenomenex, Torrence, CA). The mobile phase consisted of 10 mM ammonium acetate (pH 8.5) and methanol; the flow rate was 250 µl/min with a column temperature of 50 °C. The sample injection volume was 25 µl. Samples were kept at 4 °C in an autosampler prior to injection onto the analytical column.
The mass spectrometer was operated in the electrospray negative ion mode with a cone voltage of 100 V, a cone gas flow rate of 117 L/h, and a devolution gas flow rate of 998 L/h.
The temperature of the desolvation region was 400 °C, and the temperature of the source region was 120 °. Fragmentation for all compounds was performed using argon as the collision gas at a cell pressure of 2.1 x 10 -3 torr. The collision energy was 19 V. All eicosanoids were detected using negative ionization and multiple-reaction monitoring of the transition ions for eicosanoids products and their internal standards.
Statistical analysis
Student's t-test was used to determine the statistical differences between various experimental groups; a value of p<0.05 was considered to be significant. whereas for cells treated with 1.7 ul/ml, the proportions of early apopotosis and late apoptosis necrotic cells were 12.6% and 86.0%, respectively. Further evidence of the multi-herb mediated production of apoptosis is provided by the concentration-response of propidium iodide binding to nucleic acids in later stages of cell death (Fig 2B) . Fig 3A) and 5-HETE (Fig 3B) . More impressive, however, was the cellular decline in 12-HETE levels resulting from inhibition of 12-LOX activity. At concentrations of Zyflamend as low as 0.25 µl/min there was a significant reduction in 12-HETE levels compared to untreated control cells (P < 0.05). This relatively low concentration of Zyflamend had no effect on cellular PGE 2 levels. The highest concentration of Zyflamend examined (1 µl/ml) resulted in an approximate 80% reduction in 12-HETE levels within PC3 cells (Fig 3C) .
RESULTS
Effect of
Zyflamend-mediated Inhibition of Eicosanoid
In addition to a reduction in cellular eicosanoid enzyme products, treatment of PC3 cells with
Zyflamend also produced a clear decrease in cellular content of 5-LOX protein as evidenced by
Western blot analysis (Fig 3D) . A decline in 12-LOX protein content was also evident at with Zyflamend at 2 µl/ml for 24 hr prior to being prepared for analyses of protein expression.
Proteins chosen for examination included those involved in control of apoptosis (e.g. Bcl-2, Bax, Bcl-X L ), cell cycle regulation (e.g. cyclin D1, cyclin D3, p21, p27), as well as those specifically associated with cell survival (e.g. survivin, Rb).
The 12-LOX product, 12-HETE, is known to be associated with an increase in Rb phosphorylation effectively inhibiting the functioning of this tumor suppressor protein (17).
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One of the few reported inhibitors of 12-LOX is baicalein, a component of the herb Scutellaria.
Because Scutellaria is also a component of Zyflamend, it was therefore of interest to compare the general protein and phosphorylation changes produced by both baicalein and Zyflamend.
As seen in Fig. 4 , both baicalein as well as the complex multi-herb product Zyflamend produced similar changes in phosphorylation status of cyclin D1, Cyclin D3, Bcl-2, Bcl-X L and survivin suggesting a strong similarity in the mechanism of action. In contrast to baicalein, which inhibited the expression of p21 and p27 tumor suppressor genes in PC3 cells, Zyflamend slightly increased the expression of p21 and show no significant alteration in p27 protein.
Among the most striking changes noted were the relative content and phosphorylation status of Rb proteins ( Figure 5 ). The decrease in Rb phosphorylation occurred at multiple amino acid sites including T356 (59% decrease relative to control), S807 (62% ↓), T821 (62% ↓) and T826 (78% ↓)(Kinexus data not shown). 
DISCUSSION
The link between inflammation and malignant disease, rather than a recent concern, was noticed over 150 years ago. As early as 1863, Virchow indicated that cancers tended to occur at sites of chronic inflammation (18) . It is now recognized that recurrent or persistent inflammation, whether due to exposure to specific infectious or chemical agents, radiation or physical trauma, or as a result of aberrant immune response mechanisms, may induce, promote, or influence susceptibility to carcinogenesis by causing DNA damage, inciting tissue reparative proliferation, and/or by creating a stromal "soil" that is enriched with cytokines and growth factors (19) (20) (21) (22) . It is therefore understandable why treatment or even prevention of chronic inflammation is an active area of investigation and represents a worthwhile target for 
A.
Control Zyflamend-0.28 µl/ml Zyflamend-0.57 µl/ml Zyflamend -1.14 µl/ml 
